| Literature DB >> 28569163 |
Thomas Quinn1, Michelle Frits Bs2, Johan von Heideken3, Christine Iannaccone2, Nancy A Shadick2,4, Michael Weinblatt2,4, Maura D Iversen5,6,7,8.
Abstract
BACKGROUND: Patients with rheumatoid arthritis (RA) demonstrate reduced aerobic capacity, excess cardiovascular risk, mobility limitations and are less physically active than their healthy peers. Physical activity may decrease RA disease activity through its anti-inflammatory effects and psychological and health benefits. To successfully manage RA symptoms and reduce cardiovascular risks associated with RA through increased physical activity (PA), accurate physical activity assessments are critical. Accelerometry is an objective physical activity measure, but not widely used. Validity of the Nurses' Health Study physical activity questionnaire II (NHSPAQ) has not been determined for estimation of physical activity in RA. This study examined NHSPAQ validity in adults with RA compared to accelerometry-based metabolic equivalents determined (METs) and results of performance tests. We hypothesized NHSPAQ scores would correlate moderately (0.4-0.5) with accelerometer physical activity estimates.Entities:
Keywords: Measurement validity; Physical activity; Rheumatoid arthritis
Mesh:
Year: 2017 PMID: 28569163 PMCID: PMC5452372 DOI: 10.1186/s12891-017-1589-y
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Recruitment Results for Accelerometry Trial in Rheumatoid Arthritis
Demographic and clinical characteristics of adults with rheumatoid arthritis participating in the accelerometry trial (n = 35)
| Variable | Number (%) | Mean (SD) | Median (IQR) |
|---|---|---|---|
| Female | 28 (80) | ||
| Caucasian | 34 (97) | ||
| Age (y) | 62 (10) | 62 (52–68) | |
| Married | 30 (86) | ||
| Employed | 13 (37) | ||
| Graduated high school/attended college | 14 (40) | ||
| Graduated college/attended graduate school | 21 (60) | ||
| Disease Duration (y) | 21 (11) | 19 (11–32) | |
| Medications | |||
| Biological DMARDs | 22 (63) | ||
| Methotrexate | 18 (51) | ||
| TNF inhibitor | 18 (51) | ||
| NSAIDs | 12 (34) | ||
| Steroids | 14 (40) | ||
| Disease markers | |||
| Rheumatoid factor >15 | 21 (60) | ||
| Anti-CCP positive | 24 (69) | ||
| Seropositive | 25 (71) | ||
| DAS-CRP3a | 3.2 (1.5) | 2.9 (1.9–4.3) | |
| Disease activity (RADAI) | 2.9 (2.1) | 2.3 (1.2–4.7) | |
| Self-reported outcomes (PROs) | |||
| Multi-dimensional health Assessment | 0.62 (0.54) | 0.55 (0.1–1.0) | |
| Quality of life (Euroqol Index) | 0.8 (0.2) | 0.8 (0.7–0.8) | |
| Mental health score (MHI-5)b | 79 (17.4) | 83 (73–90) | |
| Performance Measures | |||
| 20 m Timed walk (s) | |||
| Number of steps | 28 (4.5) | 26 (24.3–30.7) | |
| Time taken (seconds) | 16.1 (3.8) | 15.7 (12.9–17.4) | |
| Timed Step test (METs)a | 4.7 (0.8) | 4.8 (4.3–5.1) | |
aFrequency Missing = 1
bFrequency Missing = 4
SD Standard deviation
IQR Interquartile range
Average metabolic equivalents derived from NHSPAQ at baseline intake, and from accelerometers along with participation rates in specific physical activities among adults with RA (n = 35)
| Measure | Calculated METs Mean (SD) | Median (IQR) |
|---|---|---|
| NHSPAQ II (Baseline) | 29 (33) | 21 (8–35) |
| NHSPAQ II (Week 1) | 25 (27) | 20 (6–30) |
| ActiGraph accelerometer (week 1) | 33 (22) | 28 (18–39) |
| Participation in various physical activity modes | Number (%) | |
| Walk | 33 (94.3) | |
| Jog | 5 (14.3) | |
| Run | 1 (2.9) | |
| Swim | 5 (14.3) | |
| Bicycle | 12 (34.3) | |
| Calisthenics | 10 (28.6) | |
| Tennis | 1 (2.9) | |
| Stair climbing | 32 (91.4) |
SD Standard deviation
IQR, Interquartile range
Correlations between metabolic equivalents (METs) derived from performance tests on day of intake, self-reported disability and from accelerometers among adults with RA (n = 35)
| Variables | Correlation Strength | 95% Confidence Limits |
|---|---|---|
| NHSPAQ METs | ||
| With accelerometer METs | 0.48 | 0.15–0.70 |
| With modified step-test METs | 0.50 | 0.18–0.72 |
| With disability (MDHAQ) | −0.24 | −0.54–0.12 |
| Actigraph accelerometer METs | ||
| With modified step-test METs | 0.39 | 0.05–0.64 |
| With walk-test speed | −0.50 | −0.71–-0.19 |
| With disability (MDHAQ) | −0.21 | −0.51–0.15 |
Fig. 2Correlation between metabolic equivalents (METs) derived from the NHSPAQ and from the accelerometer in adults with Rheumatoid Arthritis. a Scatterplot of Accelerometer METs with NHSPAQ Mets with Outlier included. b Scatterplot of Accelerometer METs with NHSPAQ Mets with Outlier excluded
Fig. 3Bland-Altman plot illustrating relationship between NHSPAQ derived metabolic equivalents (METs) and METs derived from the accelerometer among adults with RA (n = 34). The figure on the left shows the Bland-Altman plot without the outlier and the one on the right with the outlier (NOTE: scale changes with deletion of outlier). The Bland-Altman plot indicates where the greatest variance in METs calculation occurs between the NHSPAQ and accelerometer trials. Upper and lower limits are +/- 1.96 standard deviations of the average difference between METs calculations